Incyte Gets FDA Approval for Rare-Blood-Cancer Treatment [MarketWatch]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: MarketWatch
Pemazyre is a fibroblast growth factor receptor inhibitor, and has been approved to treat adults living with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. "These are complex hematologic malignancies with a range of presentations, and this approval highlights Incyte's continued leadership and commitment to advancing care for patients with rare blood cancers," Chief Executive Hervé Hoppenot said. The approval was based on a Phase 2 study that evaluated the treatment's efficacy in 28 patients. Write to Dean Seal at dean.seal@wsj.com
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- Incyte Co. (NASDAQ: INCY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Incyte to Present at Upcoming Investor ConferenceBusiness Wire
- Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at TD Cowen from $88.00 to $80.00. They now have a "buy" rating on the stock.MarketBeat
- Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
INCY
Earnings
- 4/30/24 - Miss
INCY
Sec Filings
- 5/9/24 - Form SC
- 5/9/24 - Form 4
- 4/30/24 - Form 10-Q
- INCY's page on the SEC website